Less than two years after buying Chinese biotech Gracell for its cell therapy platform, AstraZeneca has reported encouraging clinical results with the lead CAR-T from the deal, GC012F (now AZD0120), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback